Janssen in Deal with Artificial Intelligence Firm
Janssen Pharmaceuticals, a Johnson & Johnson company, has signed an exclusive license agreement with BenevolentAI, a London-based artificial intelligence company, for a series of clinical-stage drug candidates.
BenevolentAI acquired a license to a number of clinical-stage drug candidates and their related portfolio of patents following using artificial intelligence technology to evaluate the potential of these small-molecule compounds.
Under the license agreement, BenevolentAI will have the sole right to develop, manufacture, and commercialize these drug candidates in all indications and in all territories. This agreement will enable BenevolentAI to accelerate its development pipeline and use its artificial intelligence technology to explore and provide a source of clinical data. The company intends to begin late-stage Phase IIb clinical trials in mid-2017. Financial terms were not disclosed.